THIS STUDY, ALONG WITH OUR GROWING ADOPTION IN SURGICAL SETTINGS, REFLECTS THE INCREASING RECOGNITION OF OUR ABILITY TO PROVIDE CRITICAL, REAL-TIME INFORMATION THAT EMPOWERS CLINICIANS TO MAKE BETTER DECISIONS AT THE POINT OF CARE, ULTIMATELY IMPROVING PATIENT OUTCOMES AND REDUCING THE BURDEN OF POST-OPERATIVE COMPLICATIONS.
I N D U S T R Y I N V E S T I G A T I O N
THIS STUDY, ALONG WITH OUR GROWING ADOPTION IN SURGICAL SETTINGS, REFLECTS THE INCREASING RECOGNITION OF OUR ABILITY TO PROVIDE CRITICAL, REAL-TIME INFORMATION THAT EMPOWERS CLINICIANS TO MAKE BETTER DECISIONS AT THE POINT OF CARE, ULTIMATELY IMPROVING PATIENT OUTCOMES AND REDUCING THE BURDEN OF POST-OPERATIVE COMPLICATIONS.
86 % lower risk of recurrent osteomyelitis – critical factors in long-term patient well-being and reduced healthcare expenditure.
• Enhanced debridement efficacy: The study highlights MolecuLight’ s ability to guide more precise and effective debridement – a cornerstones of successful wound management and infection control.
“ This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualise bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound assessment. Moving forward, we intend to continue using this technology to enhance clinical decision-making and overall patient care,” said study author Dr Shun-Cheng Chang, from Shuang-Ho Hospital.
42 www. intelligenthealth. tech